October 29, 2024 | Revvity launches the in vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark; Withings Health Solutions announces a first-of-its-kind cellular blood pressure monitor; and more.
Withings Health Solutions announced BPM Pro 2, a first-of-its-kind cellular blood pressure monitor that collects highly precise measurements while also introduces a new feature that enriches the data with context from patients’ daily lives. The Patient Insights feature streamlines clinical workflows by gathering critical information through the device, such as symptoms and medication adherence, which reduces clinical workload and frees up care teams to dedicate time to patients with the highest need. BPM Pro 2 measures heart rate and blood pressure. It comes with the future capability to take a 1-lead ECG to detect atrial fibrillation (following FDA Clearance). The device is portable, compact and designed to be user-friendly. Press release.
SEQSTER entered a strategic partnership with icometrix. This collaboration aims to enhance the detection, tracking, and management of neurological conditions, such as Alzheimer’s Disease, Multiple Sclerosis (MS), and Traumatic Brain Injury (TBI), by combining SEQSTER’s 1-Click Records with icometrix’s advanced imaging AI technology, icobrain. SEQSTER’s 1-Click Records offers a seamless solution for unifying a patient’s electronic health record (EHR) data from multiple sources, creating a longitudinal patient record. icometrix’s flagship product, icobrain, provides AI-powered analysis of MRI and CT scans, offering detailed, quantitative data that supports clinicians in making more informed decisions. When integrated, this unified platform enables healthcare providers to track disease progression with greater precision. Press release.
Myriad Genetics and Ultima Genomics announced a joint effort to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The low-cost and low-error sequencing achievable on the UG 100 may benefit several of Myriad’s emerging products that require large amounts of high-fidelity sequencing data. The Myriad Precise Molecular Residual Disease (MRD) test performs whole-genome sequencing on two samples from cancer patients—one from a tumor and one from normal tissue—to comprehensively identify tumor-specific variants for subsequent tracking in a personalized panel. With Ultima’s support, Myriad will explore the potential for the Precise MRD test to improve in both performance and cost with ppmSeq on the UG 100. Press release.
Revvity launched the in vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease. The real-time EURORealTime APOE PCR test allows simultaneous detection of the three most frequent APOE forms, designated E2, E3 and E4. Carriers of exclusively E4 exhibit the highest risk for ARIA under therapy. With the new test now available from Revvity’s EUROIMMUN, only one reaction is required using genomic DNA isolated from a single blood sample to determine the patient’s APOE genotype. Press release.
Yourgene Health (part of the Novacyt group of companies) installed the first non-invasive prenatal testing (NIPT) workflow in Colombia at Genetix. Genetix introduced its NipTest at a launch event held in Bogotá, Colombia, to raise awareness of this new local NIPT provision to clinicians in the region. The service will utilize Yourgene’s IONA Nx NIPT Workflow to deliver fast, accurate NIPT results for expectant parents in Colombia, helping to reduce turnaround times and shipping problems. Yourgene’s IONA Nx NIPT Workflow also offers Genetix a complete CE-marked in vitro diagnostic (IVD) device to establish its own quality-assured prenatal screening service in-house. Press release.
Genialis announced the commercial availability of Genialis krasID, the first biomarker algorithm that can predict patient response and clinical benefit to KRAS inhibitors (KRASi) across tissue histology and mutation type. Genialis krasID can help guide drug development from early preclinical phases (e.g., compound/MOA differentiation and selection), to clinical trials (e.g., patient selection for clinical trials and identification of combination therapies), to market access and clinical care (e.g., development of CDx and as a clinical decision tool). Genialis krasID uses machine learning (AI/ML) to model dozens of biological processes from the gene expression of patient-derived tumors, providing incomparably more information and predictive power than traditional mutation-based diagnostics. Press release.